What's the future of MASH (Metabolic Dysfunction-Associated Steatohepatitis) treatment?

The landscape of liver disease treatment is evolving rapidly. With new diagnostic tools and promising therapies in development, the future of MASH care is brighter than ever.

Gail Bridges, PharmD, October 21, 25

GLP-1s drive historic shift in traditional drug trend

GLP-1 medications drive unprecedented growth in traditional drug spending, surpassing specialty drug trends for the first time.

Ashley Holzworth-Nash, Pharm D, September 26, 25

Study finds GLP-1s show potential for managing comorbid depression and anxiety

GLP-1s may offer benefits beyond managing blood sugar.

July 17, 25

Express Scripts expands Patient Assurance Program to drive affordability and access to GLP-1s

Express Scripts will add GLP-1s for weight loss to the Patient Assurance Program (PAP), made possible by collaboration with Lilly and Novo Nordisk.

July 10, 25

Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

• Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible • New offering helps employers meet growing ...

May 21, 25

New Evernorth EnReachRx model expands its suite of GLP-1 solutions, works to improve patient outcomes and drive value

May 02, 25